0000899243-23-001330.txt : 20230109
0000899243-23-001330.hdr.sgml : 20230109
20230109180311
ACCESSION NUMBER: 0000899243-23-001330
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230105
FILED AS OF DATE: 20230109
DATE AS OF CHANGE: 20230109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ARMEN GARO H
CENTRAL INDEX KEY: 0000935679
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 23519191
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-05
0
0001098972
AGENUS INC
AGEN
0000935679
ARMEN GARO H
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
1
1
0
0
Chairman and CEO
Common Stock
2023-01-05
4
A
0
241383
2.45
A
1249167
D
Common Stock
125969
I
See Footnote
Common Stock
579000
I
See Footnote
Stock Option
2.45
2023-01-05
4
A
0
2400000
0.00
A
2033-01-05
Common Stock
2400000
2400000
D
Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
$2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.
Shares are held in Dr. Armen's IRA accounts.
Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
/s/ Christine Klaskin, as attorney-in-fact for Garo H. Armen
2023-01-09